This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

Feuerstein graduated from Emory University with a bachelor's degree in political science.

Adam Feuerstein
By This Author:
Page 3 of 583

Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1

By Adam Feuerstein

The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.

01:09PM 01/08/15

Biogen's Nerve Repair Drug Yields Mixed Results in Key Eye Trial

By Adam Feuerstein

Anti-LINGO-1 is Biogen's most important pipeline drug candidate.

08:34AM 01/08/15

Biogen Idec's Critical Nerve Repair Drug is Poised for Big News -- Soon

By Adam Feuerstein

Study results from the most important drug in Biogen Idec's pipeline are expected as early as Monday. Here are essential points you need to know.

06:15AM 01/08/15

Alkermes CEO: Our Proprietary Drug Pipeline Is 'Maturing Beautifully'

By Adam Feuerstein

With two positive data releases in consecutive days this week, Alkermes is enjoying a strong start to the year.

10:49AM 01/07/15

Public Shame for Biotechs Not Webcasting 'JPM15' Breakout Sessions

By Adam Feuerstein

In a blow to investor transparency, an embarrassingly small number of healthcare companies are webcasting their Q&A breakout sessions at next week's J.P. Morgan Healthcare Conference.

03:08PM 01/06/15

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

By Adam Feuerstein

TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.

11:52AM 01/06/15

Brainstorm Stem-Cell Therapy Continues to Show Treatment Effect in ALS Patients

By Adam Feuerstein

Final results from a mid-stage study of Brainstorm's NurOwn therapy show a slowing of disease progression in some ALS patients.

10:52AM 01/05/15

Cempra Oral Antibiotic Effective Against Hard-to-Treat Pneumonia

By Adam Feuerstein

Cempra designed solithromycin to be potent against strains of pneumonia-causing bacteria which have grown resistant to other macrolides.

10:32PM 01/04/15

Biotech Stocks 2014: The Best, Worst and Fastest-Growing

By Adam Feuerstein

Once again, biotech stocks greatly outperformed the broader market in 2014.

08:33AM 01/02/15

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

By Adam Feuerstein

Another crazy and profitable year in biotech investing was captured 140 characters at a time.

06:00AM 12/29/14

Page 3 of 583

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs